- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05194059
'Activity Pacing' in PLWH With Fatigue Symptoms. (ActiPacMAN)
January 16, 2023 updated by: Paola Cinque, Scientific Institute San Raffaele
ActiPacMAN: 'Activity Pacing' in PLWH With Fatigue Symptoms. Monitoring Through the Combined Use of Actigraphy and Mobile App Notifications
Physical activity helps to improve health and prevent chronic diseases.
However, the fatigue usually hampers the training and execution of physical exercises, especially in people with chronic fatigue syndromes (CFCs), such as persons living with HIV (PLWH).
We hypothesize that the "activity pacing", i.e. the strategy to optimize daily physical activity into manageable exercises in a way that should not exacerbate fatigue symptoms, may help a progressive improvement in physical activity of a group of PLWH with fatigue symptoms.
Motivation and adherence to exercise will be monitored through the use of digital supports.
Study Overview
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Milan, Italy, 20127
- Department of Infectious Diseases
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- of age ≥18 years;
- either sedentary or already practicing mild/moderate physical activity (at least 150 minutes of moderate-intensity physical activity throughout the week);
- able to sign the informed consent.
Exclusion Criteria:
The study will exclude HIV+ individuals:
- with any HIV-related disease requiring hospitalization in the 6 weeks before enrolment;
- with medical conditions (e.g. neurologic, muscular-skeletal, cardiovascular diseases) contraindicating non agonistic exercise, as established by a sport medicine specialist;
- currently abusing of substance or alcohol;
- already performing physical activity at higher level than the current WHO recommendations (30 minutes of moderate activity 5 times a week).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental Group
Participants will follow a personalized activity pacing program for 16 weeks with the support of a heath band and a mobile application for tablet
|
Participants will follow a personalized activity pacing program
|
No Intervention: Control Group
Participants will follow a personalized activity pacing program for 16 weeks without any other support
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Activity pacing improvement
Time Frame: 16 week
|
To compare the improvement in the physical fitness between the Experimental Group and Control Group
|
16 week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 3, 2021
Primary Completion (Actual)
October 28, 2022
Study Completion (Actual)
October 28, 2022
Study Registration Dates
First Submitted
January 3, 2022
First Submitted That Met QC Criteria
January 3, 2022
First Posted (Actual)
January 18, 2022
Study Record Updates
Last Update Posted (Actual)
January 18, 2023
Last Update Submitted That Met QC Criteria
January 16, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ActiPacMAN
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hiv
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Hospital Clinic of BarcelonaCompletedIntegrase Inhibitors, HIV; HIV PROTEASE INHIBSpain
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
Clinical Trials on Home-based physical activity
-
Scientific Institute San RaffaeleIstituto Ortopedico GaleazziRecruiting
-
University Hospital of FerraraUniversità degli Studi di FerraraRecruitingChronic Kidney Disease Stage 5 on DialysisItaly
-
Centre Jean PerrinRecruitingHER2 Positive Breast CancerFrance
-
AHS Cancer Control AlbertaCross Cancer InstituteCompleted
-
University Hospital, GrenobleAGIR à DomNot yet recruitingAnorexia NervosaFrance
-
Aveiro UniversityFundação para a Ciência e a Tecnologia; Centro Hospitalar do Baixo VougaCompletedInterstitial Lung Diseases (ILD)Portugal
-
Children's Hospital of Eastern OntarioHeart and Stroke Foundation of CanadaRecruitingCongenital Heart DefectCanada
-
University of Illinois at Urbana-ChampaignNational Institute on Aging (NIA)Completed
-
University of Illinois at Urbana-ChampaignNational Multiple Sclerosis SocietyCompleted
-
Yale UniversityNational Cancer Institute (NCI)Completed